PHASE 2B DATA IN DEGENERATIVE DISC DISEASE STRENGTHEN THE HYPOTHESIS IN HERNIATED DISC
STA363 has previously been evaluated in a clinical phase 2b within degenerative disc diseases in a total of 110 patients. The results from the phase 2b study strengthen our belief in treatment for herniated discs. This primarily due to the following:
- STA363 demonstrated a good safety profile for up to 12 months
- In the high dose of STA363, a statistically significant difference in disc intensity was established, indicating that STA363 affects the disc in the intended way
- In both high and low doses of STA363, a dose-dependent statistically significant difference was established in disc height, a clear sign of a reduced disc volume.